We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Syndax (SNDX) Keep the Earnings Streak Alive This Quarter?
Read MoreHide Full Article
Looking for a stock that might be in a good position to beat earnings at its next report? Consider Syndax Pharmaceuticals, Inc. (SNDX - Free Report) , a firm in the Medical - Biomedical and Genetics industry which could be a great candidate for another beat.
This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. In fact, in these reports, SNDX has beaten estimates by at least 10% in both cases, suggesting it has a nice short-term history of crushing expectations.
Earnings in Focus
Two quarters ago, SNDX was expected to post a loss of 79 cents per share, while it actually produced a loss of 70 cents per share, a beat of 11.4%. Meanwhile, for the most recent quarter, the company looked to deliver a loss of 80 cents per share, when it actually saw a loss of 68 cents per share instead, representing a 15% positive surprise.
Syndax Pharmaceuticals, Inc. Price and EPS Surprise
Thanks in part to this history, recent estimates have been moving higher for Syndax Pharmaceuticals. In fact, the Earnings ESP for SNDX is positive, which is a great sign of a coming beat.
After all, the Zacks Earnings ESP compares the most accurate estimate to the broad consensus, looking to find stocks that have seen big revisions as of late, suggesting that analysts have recently become more bullish on the company’s earnings prospects. This is the case for SNDX, as the firm currently has a Zacks Earnings ESP of 10.83%, so another beat could be around the corner.
When you add this solid Zacks Rank to a positive Earnings ESP, a positive earnings surprise happens nearly 70% of the time, so it seems pretty likely that SNDX could see another beat at its next report, especially if recent trends are any guide.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Can Syndax (SNDX) Keep the Earnings Streak Alive This Quarter?
Looking for a stock that might be in a good position to beat earnings at its next report? Consider Syndax Pharmaceuticals, Inc. (SNDX - Free Report) , a firm in the Medical - Biomedical and Genetics industry which could be a great candidate for another beat.
This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. In fact, in these reports, SNDX has beaten estimates by at least 10% in both cases, suggesting it has a nice short-term history of crushing expectations.
Earnings in Focus
Two quarters ago, SNDX was expected to post a loss of 79 cents per share, while it actually produced a loss of 70 cents per share, a beat of 11.4%. Meanwhile, for the most recent quarter, the company looked to deliver a loss of 80 cents per share, when it actually saw a loss of 68 cents per share instead, representing a 15% positive surprise.
Syndax Pharmaceuticals, Inc. Price and EPS Surprise
Syndax Pharmaceuticals, Inc. price-eps-surprise | Syndax Pharmaceuticals, Inc. Quote
Thanks in part to this history, recent estimates have been moving higher for Syndax Pharmaceuticals. In fact, the Earnings ESP for SNDX is positive, which is a great sign of a coming beat.
After all, the Zacks Earnings ESP compares the most accurate estimate to the broad consensus, looking to find stocks that have seen big revisions as of late, suggesting that analysts have recently become more bullish on the company’s earnings prospects. This is the case for SNDX, as the firm currently has a Zacks Earnings ESP of 10.83%, so another beat could be around the corner.
This is particularly true when you consider that SNDX has a great Zacks Rank #2 (Buy) which can be a harbinger of outperformance and a signal for a strong earnings profile. You can see the the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
When you add this solid Zacks Rank to a positive Earnings ESP, a positive earnings surprise happens nearly 70% of the time, so it seems pretty likely that SNDX could see another beat at its next report, especially if recent trends are any guide.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>